Tags

Type your tag names separated by a space and hit enter

Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Osteoporos Int. 2009 Sep; 20(9):1571-81.OI

Abstract

This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate. During a 2-year follow-up period, compared to those with medication possession ratio (MPR) > or = 80%, women with MPR < 80% incurred significantly higher physician care costs and hospital care costs.

INTRODUCTION

This study aimed to compare direct health care costs related to the treatment of osteoporosis and osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate.

METHODS

A cohort of 15,027 women having initiated alendronate or risedronate was identified. MPR and direct health care costs (physician care, hospital care, drugs) were assessed during a 2-year period. Regression models were used to estimate mean predicted cost for compliant (MPR > or = 80%) and noncompliant (MPR < 80%) women.

RESULTS

Mean predicted physician care cost (in Canadian dollars) was $51 among women with MPR < 80% and $34 among those with MPR > or = 80%: mean difference $17, 95% confidence interval (CI) $2-22. Mean predicted hospital care cost was $568 among women with MPR < 80% and $379 among those with MPR > or = 80%: mean difference $189, 95% CI $56-320. Mean predicted drug cost was $439 among women with MPR < 80% and $1,068 among those with MPR > or = 80%: mean difference $-639, 95% CI $-649 to -629.

CONCLUSION

Compared to compliant women, noncompliant women incurred significantly higher physician care and hospital care costs. Due to lower drug costs, total direct health care costs were lower among noncompliant women.

Authors+Show Affiliations

Faculty of Pharmacy, University of Montreal, PO Box 6128, Centre-Ville Station, Montreal, Quebec, Canada, H3C 3J7.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19107385

Citation

Blouin, J, et al. "Comparison of Direct Health Care Costs Related to the Pharmacological Treatment of Osteoporosis and to the Management of Osteoporotic Fractures Among Compliant and Noncompliant Users of Alendronate and Risedronate: a Population-based Study." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 20, no. 9, 2009, pp. 1571-81.
Blouin J, Dragomir A, Fredette M, et al. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int. 2009;20(9):1571-81.
Blouin, J., Dragomir, A., Fredette, M., Ste-Marie, L. G., Fernandes, J. C., & Perreault, S. (2009). Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 20(9), 1571-81. https://doi.org/10.1007/s00198-008-0818-5
Blouin J, et al. Comparison of Direct Health Care Costs Related to the Pharmacological Treatment of Osteoporosis and to the Management of Osteoporotic Fractures Among Compliant and Noncompliant Users of Alendronate and Risedronate: a Population-based Study. Osteoporos Int. 2009;20(9):1571-81. PubMed PMID: 19107385.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. AU - Blouin,J, AU - Dragomir,A, AU - Fredette,M, AU - Ste-Marie,L-G, AU - Fernandes,J C, AU - Perreault,S, Y1 - 2008/12/24/ PY - 2008/03/23/received PY - 2008/11/03/accepted PY - 2008/12/25/entrez PY - 2008/12/25/pubmed PY - 2010/8/31/medline SP - 1571 EP - 81 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 20 IS - 9 N2 - UNLABELLED: This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate. During a 2-year follow-up period, compared to those with medication possession ratio (MPR) > or = 80%, women with MPR < 80% incurred significantly higher physician care costs and hospital care costs. INTRODUCTION: This study aimed to compare direct health care costs related to the treatment of osteoporosis and osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate. METHODS: A cohort of 15,027 women having initiated alendronate or risedronate was identified. MPR and direct health care costs (physician care, hospital care, drugs) were assessed during a 2-year period. Regression models were used to estimate mean predicted cost for compliant (MPR > or = 80%) and noncompliant (MPR < 80%) women. RESULTS: Mean predicted physician care cost (in Canadian dollars) was $51 among women with MPR < 80% and $34 among those with MPR > or = 80%: mean difference $17, 95% confidence interval (CI) $2-22. Mean predicted hospital care cost was $568 among women with MPR < 80% and $379 among those with MPR > or = 80%: mean difference $189, 95% CI $56-320. Mean predicted drug cost was $439 among women with MPR < 80% and $1,068 among those with MPR > or = 80%: mean difference $-639, 95% CI $-649 to -629. CONCLUSION: Compared to compliant women, noncompliant women incurred significantly higher physician care and hospital care costs. Due to lower drug costs, total direct health care costs were lower among noncompliant women. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/19107385/Comparison_of_direct_health_care_costs_related_to_the_pharmacological_treatment_of_osteoporosis_and_to_the_management_of_osteoporotic_fractures_among_compliant_and_noncompliant_users_of_alendronate_and_risedronate:_a_population_based_study_ L2 - https://dx.doi.org/10.1007/s00198-008-0818-5 DB - PRIME DP - Unbound Medicine ER -